Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, that is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0914 that is in Phase I clinical trial to treat Graves' disease; KPS-0373, that is in Phase III clinical trial to treat Spinocerebellar degeneration; KSP- 0576 that is in Phase I clinical trial to treat interstitial cystitis and bladder pain syndrome; and KSP-0930, which is in Phase I clinical trial to treat Narcolepsy. It also develops Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply food; purchases and sells related materials; and offers system development and information processing, facility and equipment management, and information gathering and development support services. Further, it engages in information equipment rentals; insurance agency business; manufactures and sells noodles; construction contracting; and computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is based in Matsumoto, Japan.
Frequently asked questions
What sector does Kissei Pharmaceutical Co. Ltd (KSPHF) operate in?
Kissei Pharmaceutical Co. Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Kissei Pharmaceutical Co. Ltd (KSPHF) current stock price?
As of the latest data, Kissei Pharmaceutical Co. Ltd stock price is $24.50, with a previous close of $24.50.
What is Kissei Pharmaceutical Co. Ltd (KSPHF) current market capitalization?
Kissei Pharmaceutical Co. Ltd market cap is approximately 1.03 billion.
What is Kissei Pharmaceutical Co. Ltd (KSPHF) Earnings Per Share (EPS)?
The trailing EPS is $2.17.
What is Kissei Pharmaceutical Co. Ltd (KSPHF) Price-to-Earnings (P/E) ratio?
Kissei Pharmaceutical Co. Ltd current P/E ratio is 11.29.
What is Kissei Pharmaceutical Co. Ltd (KSPHF) EBITDA?
Kissei Pharmaceutical Co. Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 2.22 billion.
Does Kissei Pharmaceutical Co. Ltd (KSPHF) pay dividends?
Yes. Kissei Pharmaceutical Co. Ltd pays semiannual dividends with an annualized yield of 7.45% and an estimated annual payout of $1.83 per share.
When is the next ex-dividend date for Kissei Pharmaceutical Co. Ltd (KSPHF)?
The next ex-dividend date is scheduled for March 31, 2027.
How did Kissei Pharmaceutical Co. Ltd (KSPHF) perform in its most recent earnings report?
In the last report (June 30, 2026), Kissei Pharmaceutical Co. Ltd posted an EPS surprise of -98.98% and a revenue surprise of 5.92%.
What is Kissei Pharmaceutical Co. Ltd (KSPHF) beta (volatility) score?
Kissei Pharmaceutical Co. Ltd has a beta of -0.142, indicating lower volatility than the overall market.
